The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase I study of NC-6004, a micellar formulation of cisplatin, in combination with gemcitabine in Japanese patients with advanced solid tumors.
 
Tetsuya Hamaguchi
Honoraria - Chugai Pharma; Merck Serono; Takeda
Consulting or Advisory Role - NanoCarrier
Research Funding - Lilly Japan (Inst); MSD (Inst); NanoCarrier (Inst); Sanofi (Inst); Sumitomo Dainippon (Inst); Taiho Pharmaceutical (Inst)
 
Toshihiko Doi
Consulting or Advisory Role - AstraZeneca; Bayer Yakuhin; Chugai Pharma; Kyowa Hakko Kirin; Lilly Japan; Merck Serono; MSD; Nippon Boehringer Ingelheim; Novartis; Otsuka
Research Funding - Astellas Pharma (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Chugai Pharma (Inst); Eisai (Inst); Janssen (Inst); Lilly Japan (Inst); Merck Serono (Inst); MSD (Inst); NanoCarrier (Inst); Novartis (Inst); Pfizer (Inst); Quintiles (Inst); Sanofi (Inst); Sumitomo Group (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)
 
Kohei Shitara
Honoraria - Bayer Yakuhin; Bristol-Myers Squibb Japan; Chugai Pharma; Novartis; Sanofi; Taiho Pharmaceutical; Takeda
Consulting or Advisory Role - Bayer; Chugai Pharma; Lilly; Takeda
Research Funding - Bayer (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Dainippon Sumitomo Pharma (Inst); Lilly (Inst); MSD (Inst); Sanofi (Inst); Taiho Pharmaceutical (Inst); Yakult Honsha (Inst)
 
Satoru Iwasa
Honoraria - Chugai Pharma; Lilly Japan; Taiho Pharmaceutical; Takeda
Research Funding - Chugai Pharma (Inst); Daiichi Sankyo (Inst); Lilly Japan (Inst); Merck Serono (Inst); Novartis (Inst); Otsuka (Inst)
 
Yasuhiro Shimada
Honoraria - Chugai Pharma; Daiichi Sankyo; Lilly Japan; Taiho Pharmaceutical; Takeda
Research Funding - Lilly Japan (Inst); Merck Serono (Inst); Taiho Pharmaceutical (Inst)
 
Mitsunori Harda
Employment - NanoCarrier
Stock and Other Ownership Interests - NanoCarrier
 
Kenichiro Naito
Employment - NanoCarrier
Stock and Other Ownership Interests - NanoCarrier
 
Naoto Hayashi
Employment - NanoCarrier
Stock and Other Ownership Interests - NanoCarrier
 
Atsuhiro Masada
Employment - NanoCarrier
Stock and Other Ownership Interests - NanoCarrier
 
Atsushi Ohtsu
Employment - Celgene (I)
Research Funding - Bristol-Myers Squibb